OmniAb Q2 2023 revenue $6.9M, net loss $14.7M; adds four partners including Merck

OmniAb, Inc.

2023-Q2 EPS reported -$0.21 revenue$23,865,000

Q2 revenue $6.9M (vs $7.2M YoY); net loss $14.7M ($0.15/share) vs $10.3M loss YoY.
H1 revenue $23.9M (vs $16.8M) driven by $10M milestone from TECVAYLI first commercial sale in EU.
Added 4 new partners: Merck, Neurocrine, Stanford, Seattle Children's; total active programs 305.
Batoclimab BLA accepted in China for gMG; IMVT-1402 Phase 1 initiated; GSK milestone $2.0M earned.
Cash and equivalents $103.1M; expects year-end cash slightly higher than 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OmniAb, Inc. reported the three and six months ended June 30, 2023 results: revenue $6.9 million, net income $14.7 million, or $0.15 per share, EPS $0.15 per share.

Period: the three and six months ended June 30, 2023
Revenue: $6.9 million
Net income: $14.7 million, or $0.15 per share
EPS: $0.15 per share
Result: reported results

Exact text from the filing

related to our current partners as well as to securing additional partnerships,” he added. Second Quarter 2023 Financial Results Revenue for the second quarter of 2023 was $6.9 million, compared with $7.2 million for the same period in 2022. Milestone revenue was higher due to progress with the batoclimab program. Service revenue was lower primarily related to

View on SEC.gov

Browse all earnings releases →

OmniAb, Inc. filing history →

Source: SEC EDGAR

accession 0001846253-23-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.